Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

CTMXCytomX Therapeutics, Inc.

Nasdaq · CIK 0001501989
Filer categoryAccelerated filer
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts340

Identity from submissions API

NameCytomX Therapeutics, Inc.
CIK0001501989
TickersCTMX
ExchangesNasdaq
Entity typeoperating
CategoryAccelerated filer
SIC2834 Pharmaceutical Preparations
EIN273521219
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone650.515.3185
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
151 OYSTER POINT BLVD.
SUITE 400
SOUTH SAN FRANCISCO
CA
94080
CA
Mailing address
151 OYSTER POINT BLVD.
SUITE 400
SOUTH SAN FRANCISCO
CA
94080
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

801 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-10 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000642 005-89140 261537899 34 8118
2026-11-05 8-K 8-K 2.02,9.01 0001193125-26-449787 001-37587 261527258 34 509570 1 1
2026-11-05 10-Q 10-Q 0001193125-26-449739 001-37587 261527077 34 11146365 1 1
2026-10-28 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000070858-26-000528 005-89140 261494841 34 171584
2026-10-16 4/A FORM 4/A 0001610717-26-000442 10901
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-005484 005-89140 261281343 34 12400
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001907884-26-000014 005-89140 261278518 34 9569
2026-08-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000448 005-89140 261251758 34 8153
2026-08-06 S-8 S-8 0001193125-26-338121 333-298059 261249503 33 227565 1 1
2026-08-06 8-K 8-K 2.02,9.01 0001193125-26-338009 001-37587 261249098 34 477088 1 1
2026-08-06 10-Q 10-Q 0001193125-26-337950 001-37587 261248874 34 9860272 1 1
2026-08-05 4 FORM 4 0001610717-26-000351 7720
2026-08-05 3 FORM 3 0001610717-26-000350 10670
2026-08-03 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000070858-26-000395 005-89140 261231342 34 171510
2026-07-30 4 FORM 4 0001610717-26-000345 5680
2026-07-30 3 FORM 3 0001610717-26-000344 11085
2026-07-27 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002247 005-89140 261206069 34 11013
2026-07-27 8-K 8-K 5.02 0001193125-26-316929 001-37587 261202881 34 139395 1 1
2026-06-22 4 xslF345X06/form4.xml 0001610717-26-000280 5318
2026-06-22 8-K 8-K 5.02,5.03,5.07,9.01 0001193125-26-277631 001-37587 261107832 34 337251 1 1
2026-06-22 4 xslF345X06/form4.xml 0001610717-26-000279 5388
2026-06-22 4 xslF345X06/form4.xml 0001610717-26-000278 5373
2026-06-22 4 xslF345X06/form4.xml 0001610717-26-000277 5363
2026-06-22 4 xslF345X06/form4.xml 0001610717-26-000276 5373
2026-06-22 4 xslF345X06/form4.xml 0001610717-26-000275 5386
2026-06-22 4 xslF345X06/form4.xml 0001610717-26-000274 5373
2026-06-17 4 xslF345X06/form4.xml 0001610717-26-000229 4822
2026-06-03 8-K 8-K 1.01 0001193125-26-255467 001-37587 261060789 34 138886 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001013594-26-000617 005-89140 26989662 34 17876
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-227057 005-89140 26989100 34 21140
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001738048-26-000064 005-89140 26988784 34 18274
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001907884-26-000010 005-89140 26986638 34 9574
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-226556 005-89140 26986543 34 10865
2026-05-07 8-K 8-K 2.02,9.01 0001193125-26-211920 001-37587 26953396 34 360411 1 1
2026-05-07 10-Q 10-Q 0001193125-26-211868 001-37587 26953142 34 8283107 1 1
2026-04-30 DEFA14A DEFA14A 0001140361-26-018248 001-37587 26925685 34 1376744
2026-04-30 DEF 14A DEF 14A 0001140361-26-018237 001-37587 26925607 34 6425427 1 1
2026-04-20 PRE 14A PRE 14A 0001140361-26-015658 001-37587 26875225 34 6417860 1 1
2026-04-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-002013 005-89140 26867650 34 18230
2026-03-26 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-001034 005-89140 26799710 34 7226
2026-03-19 4 xslF345X06/form4.xml 0001610717-26-000125 4773
2026-03-19 4 xslF345X06/form4.xml 0001610717-26-000124 5629
2026-03-19 4 xslF345X06/form4.xml 0001610717-26-000123 4783
2026-03-19 4 xslF345X06/form4.xml 0001610717-26-000122 4752
2026-03-19 8-K 8-K 8.01,9.01 0001193125-26-115958 001-37587 26774236 34 635708 1 1
2026-03-18 424B5 424B5 0001193125-26-113931 333-294342 26768907 33 698636 1 1
2026-03-16 424B5 424B5 0001193125-26-108461 333-294342 26757391 33 560377
2026-03-16 S-3ASR S-3ASR 0001193125-26-108302 333-294342 26756502 33 824800 1 1
2026-03-16 8-K 8-K 2.02,9.01 0001193125-26-107152 001-37587 26754423 34 413442 1 1
2026-03-16 10-K 10-K 0001193125-26-107146 001-37587 26754419 34 16726330 1 1
2026-03-04 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001907884-26-000006 005-89140 26720806 34 9364
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000947871-26-000190 005-89140 26644297 34 7443
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-26-002019 005-89140 26641468 34 13433
2026-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-26-000388 005-89140 26601853 34 11633
2026-02-04 4 xslF345X05/form4.xml 0001610717-26-000043 9739
2026-02-04 4 xslF345X05/form4.xml 0001610717-26-000042 7386
2026-02-04 4 xslF345X05/form4.xml 0001610717-26-000041 7400
2026-02-04 4 xslF345X05/form4.xml 0001610717-26-000040 7365
2026-02-04 4 xslF345X05/form4.xml 0001610717-26-000039 8251
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001738048-25-000016 005-89140 251488390 34 17861
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-005005 005-89140 251486023 34 12009
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001013594-25-001422 005-89140 251483236 34 25944
2025-11-10 4 xslF345X05/form4.xml 0001610717-25-000372 6065
2025-11-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002911 005-89140 251461152 34 11633
2025-11-06 144 xsl144X01/primary_doc.xml 0001628280-25-050396 001-37587 251460162 33 4502
2025-11-06 8-K 8-K 2.02,9.01 0001193125-25-269533 001-37587 251458404 34 454012 1 1
2025-11-06 10-Q 10-Q 0001193125-25-269477 001-37587 251458236 34 11688407 1 1
2025-11-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002714 005-89140 251452598 34 11632
2025-10-29 4 xslF345X05/form4.xml 0001610717-25-000370 5498
2025-10-29 3 xslF345X02/form3.xml 0001610717-25-000369 10136
2025-09-30 4 xslF345X05/form4.xml 0001610717-25-000357 7793
2025-09-30 4 xslF345X05/form4.xml 0001610717-25-000356 7778
2025-09-30 4 xslF345X05/form4.xml 0001610717-25-000355 7757
2025-09-30 4 xslF345X05/form4.xml 0001610717-25-000354 7792
2025-08-21 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-110649 005-89140 251240647 34 10612
2025-08-18 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002666 333-289365 251229558 33 1786
2025-08-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000947871-25-000782 005-89140 251221548 34 7252
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003701 005-89140 251221266 34 12093
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-012267 005-89140 251219283 34 14089
2025-08-14 CORRESP filename1.htm 0001193125-25-180756 6596
2025-08-13 UPLOAD filename1.pdf 0000000000-25-008499 333-289365 40193
2025-08-13 8-K 8-K 8.01 0001193125-25-179463 001-37587 251209061 34 141116 1 1
2025-08-07 S-8 S-8 0001193125-25-175473 333-289370 251194603 33 198343 1 1
2025-08-07 S-3 S-3 0001193125-25-175465 333-289365 251194556 33 905482 1 1
2025-08-07 8-K 8-K 2.02,9.01 0000950170-25-105053 001-37587 251194277 34 409552 1 1
2025-08-07 10-Q 10-Q 0000950170-25-104991 001-37587 251193931 34 9826729 1 1
2025-08-06 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-001984 005-89140 251188313 34 11138
2025-07-29 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000780 005-89140 251159052 34 6256
2025-07-09 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-001982 005-89140 251114604 34 24686
2025-07-09 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-001981 005-89140 251114598 34 26114
2025-06-17 4 xslF345X05/form4.xml 0001610717-25-000236 10115
2025-06-17 4 xslF345X05/form4.xml 0001610717-25-000235 8478
2025-06-17 4 xslF345X05/form4.xml 0001610717-25-000234 9333
2025-06-13 4 xslF345X05/form4.xml 0001610717-25-000215 5253
2025-06-13 4 xslF345X05/form4.xml 0001610717-25-000214 5322
2025-06-13 4 xslF345X05/form4.xml 0001610717-25-000213 5307
2025-06-13 4 xslF345X05/form4.xml 0001610717-25-000212 5297
2025-06-13 4 xslF345X05/form4.xml 0001610717-25-000211 5308
2025-06-13 4 xslF345X05/form4.xml 0001610717-25-000210 5307
2025-06-13 4 xslF345X05/form4.xml 0001610717-25-000209 5320
2025-06-13 8-K 8-K 5.02,5.07,9.01 0001193125-25-140739 001-37587 251046573 34 326620 1 1
2025-05-28 8-K 8-K 8.01 0001193125-25-129470 001-37587 25995457 34 135982 1 1
2025-05-20 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001013594-25-000691 005-89140 25970650 34 23049 1 1
2025-05-20 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-075515 005-89140 25970645 34 114937
2025-05-20 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-013803 005-89140 25969129 34 34846
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-007872 005-89140 25953332 34 29764
2025-05-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-002330 005-89140 25947070 34 17042
2025-05-13 8-K 8-K 8.01,9.01 0001193125-25-118805 001-37587 25939945 34 400678 1 1
2025-05-12 424B5 424B5 0001193125-25-117880 333-281433 25935836 33 527718
2025-05-12 8-K 8-K 2.02,8.01,9.01 0001193125-25-117245 001-37587 25932489 34 247375 1 1
2025-05-12 10-Q 10-Q 0000950170-25-068511 001-37587 25932453 34 8258617 1 1
2025-04-28 DEFA14A DEFA14A 0001140361-25-016028 001-37587 25880609 34 4778564
2025-04-28 DEF 14A DEF 14A 0001140361-25-016026 001-37587 25880561 34 5931835 1 1
2025-03-20 4 xslF345X05/form4.xml 0001610717-25-000086 5569
2025-03-20 4 xslF345X05/form4.xml 0001610717-25-000085 4731
2025-03-20 4 xslF345X05/form4.xml 0001610717-25-000084 4695
2025-03-20 4 xslF345X05/form4.xml 0001610717-25-000083 4649
2025-03-20 4 xslF345X05/form4.xml 0001610717-25-000082 4724
2025-03-06 S-8 S-8 0001193125-25-048412 333-285594 25715221 33 85713
2025-03-06 8-K 8-K 2.02,9.01 0000950170-25-034585 001-37587 25715161 34 342323 1 1
2025-03-06 10-K 10-K 0000950170-25-034575 001-37587 25715108 34 14369550 1 1
2025-02-26 8-K 8-K 3.01 0001193125-25-036794 001-37587 25670631 34 147983 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-25-000043 005-89140 25625164 34 9570
2025-02-10 4/A xslF345X05/form4.xml 0001610717-25-000020 12512
2025-02-06 4 xslF345X05/form4.xml 0001610717-25-000019 11570
2025-02-06 4 xslF345X05/form4.xml 0001610717-25-000018 11541
2025-02-06 4 xslF345X05/form4.xml 0001610717-25-000017 11578
2025-02-06 4 xslF345X05/form4.xml 0001610717-25-000016 12418
2025-02-03 8-K 8-K 5.02 0001193125-25-019257 001-37587 25582446 34 148643 1 1
2025-01-06 8-K 8-K 2.05 0001193125-25-002165 001-37587 25511179 34 153166 1 1
2024-11-14 SC 13G/A AMENDMENT NO. 3 TO SCHEDULE 13G 0000921895-24-002717 005-89140 241462947 34 283447
2024-11-14 SC 13G/A AMENDMENT NO.3 0001214659-24-019106 005-89140 241461374 34 136549
2024-11-14 SC 13G/A cormorant-ctmx093024a1.htm 0001172661-24-005044 005-89140 241460728 34 87721
2024-11-14 SC 13G/A JANUS AMENDMENT 0001274173-24-000114 005-89140 241459396 34 13103
2024-11-07 8-K 8-K 2.02,9.01 0000950170-24-123314 001-37587 241435694 34 413783 1 1
2024-11-07 10-Q 10-Q 0000950170-24-123249 001-37587 241435425 34 8155558 1 1
2024-08-22 4 xslF345X05/form4.xml 0001610717-24-000436 10360
2024-08-22 4 xslF345X05/form4.xml 0001610717-24-000435 8785
2024-08-22 4 xslF345X05/form4.xml 0001610717-24-000434 8891
2024-08-22 4 xslF345X05/form4.xml 0001610717-24-000433 8789
2024-08-22 4 xslF345X05/form4.xml 0001610717-24-000432 9631
2024-08-19 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-08-19 16:00:00 9999999995-24-002578 333-281433 241222517 33 1793
2024-08-15 CORRESP filename1.htm 0001193125-24-201304 6923
2024-08-15 UPLOAD filename1.pdf 0000000000-24-009362 333-281433 40085
2024-08-09 S-3 S-3 0001193125-24-197826 333-281433 241192601 33 966559
2024-08-08 8-K 8-K 2.02,9.01 0000950170-24-093936 001-37587 241188314 34 417565 1 1
2024-08-08 10-Q 10-Q 0000950170-24-093865 001-37587 241188093 34 7932676 1 1
2024-06-17 8-K 8-K 5.02 0001193125-24-162652 001-37587 241048798 34 150197 1 1
2024-06-14 4 xslF345X05/form4.xml 0001610717-24-000339 7403
2024-05-22 SC 13G JHBIFCytomX051324.txt 0001274173-24-000069 005-89140 24973269 34 12959
2024-05-17 4 xslF345X05/form4.xml 0001610717-24-000248 5328
2024-05-17 4 xslF345X05/form4.xml 0001610717-24-000247 5259
2024-05-17 4 xslF345X05/form4.xml 0001610717-24-000246 5313
2024-05-17 4 xslF345X05/form4.xml 0001610717-24-000245 5300
2024-05-17 4 xslF345X05/form4.xml 0001610717-24-000244 5314
2024-05-17 4 xslF345X05/form4.xml 0001610717-24-000243 5325
2024-05-17 4 xslF345X05/form4.xml 0001610717-24-000242 5326
2024-05-17 8-K 8-K 5.03,5.07,9.01 0001193125-24-141699 001-37587 24959447 34 201843 1 1
2024-05-13 SC 13G sc13g.htm 0000929638-24-001775 005-89140 24938838 34 113377
2024-05-08 8-K 8-K 8.01,9.01 0001193125-24-134284 001-37587 24926938 34 177424 1 1
2024-05-08 8-K 8-K 2.02,9.01 0000950170-24-055598 001-37587 24925785 34 387329 1 1
2024-05-08 10-Q 10-Q 0000950170-24-055588 001-37587 24925724 34 6932748 1 1
2024-05-01 DEFA14A DEFA14A 0001193125-24-126170 001-37587 24899836 34 20383
2024-04-04 DEFA14A DEFA14A 0001140361-24-017973 001-37587 24823563 34 3926391
2024-04-04 DEF 14A DEF 14A 0001140361-24-017969 001-37587 24823540 34 2810224
2024-03-28 4 xslF345X05/form4.xml 0001610717-24-000190 7671
2024-03-25 PRE 14A PRE 14A 0001140361-24-015062 001-37587 24780152 34 2836498
2024-03-22 4 xslF345X05/form4.xml 0001610717-24-000181 5308
2024-03-22 3 xslF345X02/form3.xml 0001610717-24-000180 10447
2024-03-22 8-K 8-K 5.02,5.03,9.01 0001193125-24-075211 001-37587 24775242 34 324395 1 1
2024-03-21 4 xslF345X05/form4.xml 0001610717-24-000179 4648
2024-03-21 4 xslF345X05/form4.xml 0001610717-24-000178 5569
2024-03-21 4 xslF345X05/form4.xml 0001610717-24-000177 4733
2024-03-21 4 xslF345X05/form4.xml 0001610717-24-000176 4724
2024-03-21 4 xslF345X05/form4.xml 0001610717-24-000175 6117
2024-03-11 S-8 S-8 0001193125-24-064845 333-277819 24738475 33 78561
2024-03-11 8-K 8-K 2.02,9.01 0000950170-24-029207 001-37587 24737925 34 367225 1 1
2024-03-11 10-K 10-K 0000950170-24-029191 001-37587 24737906 34 13046457 1 1
2024-02-14 SC 13G/A AMENDMENT NO. 2 0001214659-24-002867 005-89140 24637365 34 85445
2024-02-14 SC 13G/A AMENDMENT NO. 2 TO SCHEDULE 13G 0000921895-24-000454 005-89140 24633512 34 283569
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-020727 005-89140 24627896 34 13108
2024-01-19 4 xslF345X05/form4.xml 0001610717-24-000036 10612
2024-01-19 4 xslF345X05/form4.xml 0001610717-24-000035 9689
2024-01-19 4 xslF345X05/form4.xml 0001610717-24-000034 9774
2024-01-19 4 xslF345X05/form4.xml 0001610717-24-000033 11158
2024-01-19 4 xslF345X05/form4.xml 0001610717-24-000032 9764
2024-01-19 4 xslF345X05/form4.xml 0001610717-24-000031 9734
2023-12-22 4 xslF345X05/form4.xml 0001610717-23-000423 5593
2023-12-22 4 xslF345X05/form4.xml 0001610717-23-000422 4747
2023-12-22 4 xslF345X05/form4.xml 0001610717-23-000421 6140
2023-12-22 4 xslF345X05/form4.xml 0001610717-23-000420 4671
2023-12-22 4 xslF345X05/form4.xml 0001610717-23-000419 4757
2023-12-19 4 xslF345X05/form4.xml 0001610717-23-000412 7350
2023-12-19 4 xslF345X05/form4.xml 0001610717-23-000411 8008
2023-12-19 4 xslF345X05/form4.xml 0001610717-23-000410 8790
2023-12-19 4 xslF345X05/form4.xml 0001610717-23-000409 7322
2023-12-19 4 xslF345X05/form4.xml 0001610717-23-000408 7163
2023-11-07 8-K 8-K 2.02,9.01 0000950170-23-060221 001-37587 231383619 34 502291 1 1
2023-11-07 10-Q 10-Q 0000950170-23-060201 001-37587 231383533 34 10253515 1 1
2023-09-22 4 xslF345X05/form4.xml 0001610717-23-000299 6373
2023-09-22 4 xslF345X05/form4.xml 0001610717-23-000298 7765
2023-09-22 4 xslF345X05/form4.xml 0001610717-23-000297 7219
2023-09-22 4 xslF345X05/form4.xml 0001610717-23-000296 6296
2023-08-28 424B3 424B3 0001193125-23-221648 333-274010 231209465 33 188250
2023-08-25 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-08-25 16:00:00 9999999995-23-002501 333-274010 231209950 33 1744
2023-08-24 8-K 8-K 1.01 0001193125-23-220087 001-37587 231202197 34 145587 1 1
2023-08-23 CORRESP filename1.htm 0001193125-23-219080 10118
2023-08-22 UPLOAD filename1.pdf 0000000000-23-009183 40297
2023-08-17 D xslFormDX01/primary_doc.xml 06b 0001567619-23-006953 021-489946 231179313 33 13971
2023-08-16 S-3 S-3 0001193125-23-213683 333-274010 231176371 33 307827
2023-08-08 8-K 8-K 2.02,9.01 0000950170-23-039793 001-37587 231151300 34 441863 1 1
2023-08-08 10-Q 10-Q 0000950170-23-039761 001-37587 231151104 34 9889087 1 1
2023-07-20 4 xslF345X05/form4.xml 0001610717-23-000208 5396
2023-07-20 3 FORM 3 0001567619-23-006641 10756
2023-07-03 8-K 8-K 1.01,3.02,9.01 0001193125-23-180722 001-37587 231063154 34 734038 1 1
2023-06-20 8-K 8-K 5.07 0001193125-23-170124 001-37587 231025059 34 155056 1 1
2023-06-16 4 xslF345X04/form4.xml 0001610717-23-000183 5188
2023-06-16 4 xslF345X04/form4.xml 0001610717-23-000182 5201
2023-06-16 4 xslF345X04/form4.xml 0001610717-23-000181 5216
2023-06-16 4 xslF345X04/form4.xml 0001610717-23-000180 5214
2023-06-16 4 xslF345X04/form4.xml 0001610717-23-000179 5213
2023-06-16 4 xslF345X04/form4.xml 0001610717-23-000178 5202
2023-05-23 4 xslF345X04/form4.xml 0001610717-23-000061 7375
2023-05-09 8-K 8-K 2.02,9.01 0000950170-23-019674 001-37587 23902117 34 457194 1 1
2023-05-09 10-Q 10-Q 0000950170-23-019654 001-37587 23902052 34 8504143 1 1
2023-04-27 DEFA14A DEFA14A 0001140361-23-020949 001-37587 23857215 34 3968177
2023-04-27 DEF 14A DEF 14A 0001140361-23-020944 001-37587 23857168 34 3165919
2023-03-31 4 xslF345X04/form4.xml 0001140361-23-015503 4151
2023-03-29 4 xslF345X04/form4.xml 0001140361-23-014592 4806
2023-03-29 3 xslF345X02/form3.xml 0001140361-23-014591 29052
2023-03-27 S-8 S-8 0001193125-23-080477 333-270869 23764773 33 86512
2023-03-27 8-K 8-K 2.02,9.01 0000950170-23-009999 001-37587 23764672 34 463277 1 1
2023-03-27 10-K 10-K 0000950170-23-009991 001-37587 23764648 34 24013025 1 1
2023-03-27 10-K/A 10-K/A 0000950170-23-009984 001-37587 23764574 34 33415617 1 1
2023-03-20 4 xslF345X04/form4.xml 0001140361-23-012619 4618
2023-03-20 4 xslF345X04/form4.xml 0001140361-23-012618 5455
2023-03-20 4 xslF345X04/form4.xml 0001140361-23-012617 4546
2023-03-20 4 xslF345X04/form4.xml 0001140361-23-012616 4533
2023-03-20 4 xslF345X04/form4.xml 0001140361-23-012615 6003
2023-03-20 4 xslF345X04/form4.xml 0001140361-23-012614 4616
2023-03-10 8-K 8-K 7.01 0001193125-23-067531 001-37587 23723393 34 148358 1 1
2023-02-24 8-K 8-K 4.02 0001193125-23-047460 001-37587 23662311 34 153418 1 1
2023-02-14 SC 13G/A SCHEDULE 13G/A, AMENDMENT #2 0000899140-23-000386 005-89140 23629421 34 52284
2023-02-14 SC 13G/A AMENDMENT NO. 1 0001214659-23-002395 005-89140 23628405 34 85556
2023-02-14 SC 13G/A CYTOMX THERAPEUTICS, INC. 0000902664-23-001738 005-89140 23624014 34 61099
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-015751 005-89140 23602915 34 12996
2023-02-06 4 FORM 4 0001567619-23-001930 10829
2023-02-06 4 FORM 4 0001567619-23-001929 11414
2023-02-06 4 FORM 4 0001567619-23-001928 10126
2023-02-06 4 FORM 4 0001567619-23-001927 10215
2023-01-05 8-K 8-K 1.01 0001193125-23-002398 001-37587 23511432 34 154622 1 1
2022-11-22 8-K 8-K 1.01 0001193125-22-290176 001-37587 221407191 34 153425 1 1
2022-11-08 8-K 8-K 2.02,9.01 0000950170-22-023210 001-37587 221368945 34 532495 1 1
2022-11-08 10-Q 10-Q 0000950170-22-023190 001-37587 221368795 34 9393008 1 1
2022-09-26 CT ORDER filename1.pdf 20220926,20220926 9999999997-22-004269 001-37587 221264997 34 129924
2022-09-23 8-K 8-K 5.02 0001193125-22-250137 001-37587 221262398 34 147370 1 1
2022-09-13 8-K 8-K 5.02 0001193125-22-243709 001-37587 221240863 34 148404 1 1
2022-08-12 4 FORM 4 0001567619-22-015868 8026
2022-08-12 4 FORM 4 0001567619-22-015866 8076
2022-08-12 4 FORM 4 0001567619-22-015864 8081
2022-08-12 4 FORM 4 0001567619-22-015863 7999
2022-08-04 8-K 8-K 2.02,9.01 0000950170-22-014751 001-37587 221136681 34 512235 1 1
2022-08-04 10-Q 10-Q 0000950170-22-014737 001-37587 221136533 34 7851453 1 1
2022-07-29 SC 13G/A AMENDMENT NO. 1 TO THE SCHEDULE 13G 0000921895-22-002304 005-89140 221121354 34 277763
2022-07-25 SC 13G p722221sc13g.htm 0001214659-22-009141 005-89140 221103308 34 92555
2022-07-21 4 FORM 4 0001567619-22-014301 6944
2022-07-21 4 FORM 4 0001567619-22-014300 8327
2022-07-21 4 FORM 4 0001567619-22-014299 7525
2022-07-21 4 FORM 4 0001567619-22-014298 6634
2022-07-21 4 FORM 4 0001567619-22-014297 6667
2022-07-21 4 FORM 4 0001567619-22-014296 6643
2022-07-13 8-K 8-K 2.05,5.02 0001193125-22-192874 001-37587 221081173 34 150545 1 1
2022-07-08 SC 13G us23284f1057_070822.txt 0000834237-22-010281 005-89140 221075042 34 12220
2022-07-06 8-K 8-K 8.01 0001193125-22-188577 001-37587 221068791 34 149190 1 1
2022-06-21 8-K 8-K 5.07 0001193125-22-177650 001-37587 221028310 34 154901 1 1
2022-06-17 4 FORM 4 0001567619-22-013075 5557
2022-06-17 4 FORM 4 0001567619-22-013074 5542
2022-06-17 4 FORM 4 0001567619-22-013073 5529
2022-06-17 4 FORM 4 0001567619-22-013072 5554
2022-06-17 4 FORM 4 0001567619-22-013071 5490
2022-06-17 4 FORM 4 0001567619-22-013070 5543
2022-06-17 4 FORM 4 0001567619-22-013069 5555
2022-05-11 4 FORM 4 0001567619-22-010091 11210
2022-05-05 8-K 8-K 2.02,9.01 0000950170-22-007835 001-37587 22896389 34 426819 1 1
2022-05-05 10-Q 10-Q 0000950170-22-007806 001-37587 22896154 34 6897830 1 1
2022-04-27 DEFA14A DEFA14A 0001140361-22-016245 001-37587 22859938 34 5277506
2022-04-27 DEF 14A DEF 14A 0001140361-22-016242 001-37587 22859904 34 3066869
2022-04-14 8-K 8-K 5.02 0001193125-22-105580 001-37587 22827445 34 142678 1 1
2022-03-28 3 FORM 3 0001567619-22-007578 20041
2022-03-23 8-K 8-K 5.02 0001193125-22-082793 001-37587 22763590 34 142358 1 1
2022-03-09 3 FORM 3 0001567619-22-006664 15767
2022-03-04 424B5 FORM 424B5 0001193125-22-066325 333-258510 22715323 33 580423
2022-03-04 S-8 S-8 0001193125-22-066309 333-263321 22715201 33 77448
2022-03-01 8-K 8-K 2.02,9.01 0000950170-22-002526 001-37587 22698073 34 438890 1 1
2022-03-01 10-K 10-K 0000950170-22-002519 001-37587 22697950 34 16107361 1 1
2022-02-14 SC 13G/A SCHEDULE 13G (AMENDMENT NO. 2) 0000899140-22-000335 005-89140 22633549 34 54160
2022-02-14 8-K 8-K 5.02 0001193125-22-041752 001-37587 22632213 34 144885 1 1
2022-02-14 SC 13G/A CYTOMX THERAPEUTICS, INC. 0001104659-22-022771 005-89140 22631933 34 93978
2022-02-14 SC 13G/A CYTOMX THERAPEUTICS, INC. 0000902664-22-001608 005-89140 22625837 34 63134
2022-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-22-016943 005-89140 22606950 34 12997
2022-02-07 8-K 8-K 5.02 0001193125-22-029142 001-37587 22595644 34 144290 1 1
2022-02-04 4 FORM 4 0001567619-22-002525 7625
2022-02-04 4 FORM 4 0001567619-22-002524 7542
2022-02-04 4 FORM 4 0001567619-22-002523 7578
2022-02-04 4 FORM 4 0001567619-22-002522 7554
2022-02-04 4 FORM 4 0001567619-22-002521 8434
2022-02-03 SC 13G/A us23284f1057_020322.txt 0000834237-22-006265 005-89140 22588998 34 13181
2022-02-01 SC 13G/A cytomx13ga2_123121.htm 0001040188-22-000014 005-89140 22577767 34 40583
2022-01-10 8-K FORM 8-K 7.01,9.01 0001171843-22-000174 001-37587 22519745 34 2673779 1 1
2022-01-03 SC 13G sc13g07422010_01032022.htm 0000921895-22-000008 005-89140 22502593 34 284302
2021-12-29 CT ORDER filename1.pdf 20211229,20211229 9999999997-21-006041 001-37587 211526929 34 128927
2021-12-08 SC 13G formsc13g.htm 0001493152-21-030804 005-89140 211478366 34 159425
2021-11-04 8-K 8-K 2.02,9.01 0000950170-21-003067 001-37587 211380107 34 469857 1 1
2021-11-04 10-Q 10-Q 0000950170-21-003053 001-37587 211379937 34 9023149 1 1
2021-10-26 4 FORM 4 0001567619-21-018720 8075
2021-10-26 4 FORM 4 0001567619-21-018719 8031
2021-10-26 4 FORM 4 0001567619-21-018718 8114
2021-10-26 4 FORM 4 0001567619-21-018717 8043
2021-10-26 4 FORM 4 0001567619-21-018716 8067
2021-10-07 4 FORM 4 0001567619-21-018045 5616
2021-10-07 3 FORM 3 0001567619-21-018044 10885
2021-10-04 8-K 8-K 5.02 0001193125-21-290428 001-37587 211301143 34 150373 1 1
2021-08-18 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-08-18 16:00:00 9999999995-21-003235 333-258510 211188311 33 1713
2021-08-17 S-3/A S-3/A 0001193125-21-248190 333-258510 211180776 33 331929
2021-08-16 CORRESP filename1.htm 0001193125-21-248193 7622
2021-08-13 4 FORM 4 0001567619-21-015554 7958
2021-08-12 UPLOAD filename1.pdf 0000000000-21-009876 40277
2021-08-05 S-3 S-3 0001193125-21-237879 333-258510 211149337 33 658295
2021-08-05 10-Q 10-Q 0000950170-21-000946 001-37587 211148700 34 8370506 1 1
2021-08-05 8-K 8-K 2.02,9.01 0000950170-21-000939 001-37587 211148486 34 443363 1 1
2021-06-22 8-K 8-K 5.07 0001193125-21-195380 001-37587 211032548 34 159490 1 1
2021-06-21 4 FORM 4 0001567619-21-012419 6080
2021-06-17 4 FORM 4 0001567619-21-012372 5542
2021-06-17 4 FORM 4 0001567619-21-012371 5557
2021-06-17 4 FORM 4 0001567619-21-012369 5520
2021-06-17 4 FORM 4 0001567619-21-012368 5529
2021-06-17 4 FORM 4 0001567619-21-012367 5543
2021-06-17 4 FORM 4 0001567619-21-012365 5490
2021-06-17 4 FORM 4 0001567619-21-012364 5554
2021-06-16 4 FORM 4 0001567619-21-012252 11039
2021-06-08 4 FORM 4 0001567619-21-011808 5915
2021-06-08 4 FORM 4 0001567619-21-011807 4731
2021-06-08 4 FORM 4 0001567619-21-011806 4802
2021-05-06 S-8 S-8 0001193125-21-153339 333-255832 21898266 33 73186
2021-05-06 10-Q 10-Q - Q1/2021 0001564590-21-024969 001-37587 21897889 34 8255869 1 1
2021-05-06 8-K 8-K-050621 Q1-21 EARNINGS 2.02,9.01 0001564590-21-024964 001-37587 21897834 34 488470 1 1
2021-05-03 SC 13G/A AMENDMENT NO. 3 TO THE SCHEDULE 13G 0000921895-21-001197 005-89140 21884720 34 279063
2021-04-28 DEFA14A DEFA14A 0001140361-21-014778 001-37587 21864810 34 1649314
2021-04-28 DEF 14A DEF 14A 0001140361-21-014772 001-37587 21864729 34 2725505
2021-04-02 4 FORM 4 0001567619-21-007541 8841
2021-03-05 SEC STAFF LETTER filename1.pdf 9999999997-21-000557 275638
2021-03-04 8-K 8-K 5.02 0001193125-21-069514 001-37587 21714358 34 155438 1 1
2021-03-02 4 FORM 4 0001567619-21-005402 5648
2021-03-02 4 FORM 4 0001567619-21-005399 5577
2021-03-02 4 FORM 4 0001567619-21-005398 5601
2021-03-02 4 FORM 4 0001567619-21-005397 5565
2021-03-02 4 FORM 4 0001567619-21-005396 7676
2021-02-24 S-8 S-8 0001193125-21-054696 333-253452 21673682 33 84321
2021-02-24 8-K 8-K - YE 2020 EARNINGS 2.02,9.01 0001564590-21-008088 001-37587 21673194 34 472430 1 1
2021-02-24 10-K 10-K 0001564590-21-008081 001-37587 21673103 34 18575845 1 1
2021-02-18 4 OWNERSHIP DOCUMENT 0000921895-21-000498 24303
2021-02-16 SC 13G/A SC 13G/A 0001193125-21-044791 005-89140 21637596 34 66561
2021-02-11 SC 13G/A AMENDMENT NO. 2 TO THE SCHEDULE 13G 0000921895-21-000340 005-89140 21621113 34 279075
2021-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-21-017882 005-89140 21610535 34 13861
2021-02-04 SEC STAFF LETTER filename1.pdf 9999999997-21-000459 276977
2021-02-02 SC 13G/A cytomx13ga1_123120.htm 0001040188-21-000039 005-89140 21580875 34 40615
2021-01-29 SC 13G SCHEDULE 13G 0001104659-21-009413 005-89140 21571600 34 90386
2021-01-29 SC 13G/A us23284f1057_012921.txt 0000834237-21-003749 005-89140 21568707 34 13330
2021-01-26 SC 13G SCHEDULE 13G 0000899140-21-000089 005-89140 21555326 34 60914
2021-01-25 8-K 8-K 8.01,9.01 0001193125-21-016452 001-37587 21550767 34 417211 1 1
2021-01-21 424B5 424B5 0001193125-21-013638 333-228203 21542762 33 763622
2021-01-19 424B5 424B5 0001193125-21-011599 333-228203 21536323 33 764041
2021-01-19 8-K 8-K 2.02,8.01 0001193125-21-011589 001-37587 21536301 34 150645 1 1
2020-12-28 4 FORM 4 0001567619-20-021619 6721
2020-12-28 3 OWNERSHIP DOCUMENT 0000921895-20-003280 23606
2020-12-22 8-K 8-K 5.02 0001193125-20-324542 001-37587 201408149 34 149897 1 1
2020-12-18 4 FORM 4 0001567619-20-021372 5608
2020-12-18 3 FORM 3 0001567619-20-021370 10580
2020-12-07 4 FORM 4 0001567619-20-020709 4802
2020-12-07 4 FORM 4 0001567619-20-020707 4759
2020-12-07 4 FORM 4 0001567619-20-020706 4731
2020-11-10 SC 13G/A AMENDMENT NO. 1 TO THE SCHEDULE 13G 0000921895-20-002869 005-89140 201301917 34 279277
2020-11-05 8-K 8-K - Q3-20 EARNINGS 2.02,9.01 0001564590-20-051317 001-37587 201290582 34 607781 1 1
2020-11-05 10-Q 10-Q Q3/2020 0001564590-20-051302 001-37587 201290464 34 11243167 1 1
2020-10-06 8-K 8-K 5.02 0001193125-20-264740 001-37587 201226935 34 149262 1 1
2020-09-23 4 FORM 4 0001567619-20-017051 6987
2020-08-06 8-K 8-K Q2-20 EARNINGS 2.02,9.01 0001564590-20-037749 001-37587 201081782 34 372357 1 1
2020-08-06 10-Q 10-Q - Q2/2020 0001564590-20-037722 001-37587 201081597 34 9186713 1 1
2020-06-23 8-K 8-K 5.03,5.07,9.01 0001193125-20-176532 001-37587 20982067 34 188688 1 1
2020-06-19 4 FORM 4 0001567619-20-012433 5529
2020-06-18 4 FORM 4 0001567619-20-012361 5519
2020-06-17 4 FORM 4 0001567619-20-012304 13811
2020-06-17 4 FORM 4 0001567619-20-012301 5547
2020-06-17 4 FORM 4 0001567619-20-012300 13763
2020-06-17 4 FORM 4 0001567619-20-012299 5553
2020-06-17 4 FORM 4 0001567619-20-012298 13980
2020-06-02 4 FORM 4 0001567619-20-011542 4761
2020-05-29 8-K 8-K 8.01 0001193125-20-155943 001-37587 20929165 34 501512 1 1
2020-05-14 4 FORM 4 0001567619-20-010115 8295
2020-05-07 8-K 8-K-EARNINGS Q1-20 2.02,9.01 0001564590-20-022870 001-37587 20856594 34 468457 1 1

Latest XBRL company facts

One latest value per concept from companyfacts (340 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 218.00M 2026-10-31 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
dei EntityPublicFloat Entity Public Float USD 372.30M 2025-06-30 2025 FY 10-K 2026-03-16 0001193125-26-107146
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 2.95M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001140361-26-018237
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.89M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001140361-26-018237
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 10.64M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001140361-26-018237
ecd PeoTotalCompAmt PeoTotalCompAmt USD 4.74M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001140361-26-018237
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 266.25 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001140361-26-018237
ffd NetFeeAmt NetFeeAmt USD 3,237.75 2026-08-04 S-8 2026-08-06 0001193125-26-338121
ffd TtlFeeAmt TtlFeeAmt USD 3,237.75 2026-08-04 S-8 2026-08-06 0001193125-26-338121
ffd TtlOfferingAmt TtlOfferingAmt USD 23.45M 2026-08-04 S-8 2026-08-06 0001193125-26-338121
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-08-04 S-8 2026-08-06 0001193125-26-338121
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.14M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 501,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AccountsReceivableRelatedPartiesCurrent Accounts Receivable, Related Parties, Current USD 154,000 2016-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 3.52M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 16.45M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 2.21M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 16.92M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -315,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 1.06B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 2.84M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 3.80M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 5.86M 2026-01-01 2026-03-31 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 13.17M 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-03-27 0000950170-23-009984
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 80,000 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap AmortizationOfIntangibleAssets Amortization of Intangible Assets USD 109,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 25.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap Assets Assets USD 364.68M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AssetsCurrent Assets, Current USD 356.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AssetsFairValueDisclosureRecurring Assets, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) USD 321.19M 2017-09-30 2017 Q3 10-Q 2017-11-07 0001564590-17-022252
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 102,000 2026-03-31 2026 Q1 10-Q 2026-05-07 0001193125-26-211868
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1,000 2025-03-31 2025 Q1 10-Q 2025-05-12 0000950170-25-068511
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 336.45M 2018-09-30 2018 Q3 10-Q 2018-11-06 0001564590-18-027387
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD 279.39M 2019-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 110,000 2019-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 66,000 2018-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 279.28M 2019-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap AvailableForSaleSecuritiesCurrent Available-for-sale Securities, Current USD 204.81M 2018-09-30 2018 Q3 10-Q 2018-11-06 0001564590-18-027387
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 0 2021-03-31 2021 Q1 10-Q 2021-05-06 0001564590-21-024969
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 336.27M 2018-09-30 2018 Q3 10-Q 2018-11-06 0001564590-18-027387
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 314.02M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap AvailableForSaleSecuritiesNoncurrent Available-for-sale Securities, Noncurrent USD 2.02M 2016-09-30 2016 Q3 10-Q 2016-11-03 0001564590-16-027405
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 1.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap CapitalLeaseObligationsIncurred Lease Obligation Incurred USD 4.14M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 33.96M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 72.90M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 79.90M 2025-03-31 2025 Q1 10-Q 2025-05-12 0000950170-25-068511
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 189.34M 2019-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 35.49M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD 21.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 82.20M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-06 0001564590-18-027387
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 3.084 2017-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 81,620 2014-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 15.77M 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 300.00M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 170.19M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 170.19M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap CommonStockValue Common Stock, Value, Issued USD 2,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -59.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ConstructionInProgressGross Construction in Progress, Gross USD 0 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 53.28M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price USD 49.17M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-07 0001564590-19-041726
us-gaap ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress USD 10.00M 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 27.41M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 25.86M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 13.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 1.51M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 27.14M 2015-10-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap CumulativeEffectOnRetainedEarningsNetOfTax1 Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) USD -10.91M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 238,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 238,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 283,000 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-03 0001564590-16-027405
us-gaap DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain (Loss), before Tax USD -315,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredIncomeTaxesAndTaxCredits Deferred Income Taxes and Tax Credits USD -513,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 932,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2014-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap DeferredRentCredit Deferred Rent Credit USD 200,000 2016-09-30 2017 Q3 10-Q 2017-11-07 0001564590-17-022252
us-gaap DeferredRevenue Deferred Revenue USD 301.83M 2018-06-30 2018 Q2 10-Q 2018-08-08 0001564590-18-020448
us-gaap DeferredRevenueAdditions Deferred Revenue, Additions USD 31.90M 2018-01-01 2018-06-30 2018 Q2 10-Q 2018-08-08 0001564590-18-020448
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 51.51M 2018-06-30 2018 Q2 10-Q 2018-08-08 0001564590-18-020448
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 250.32M 2018-06-30 2018 Q2 10-Q 2018-08-08 0001564590-18-020448
us-gaap DeferredRevenueRefundPayments1 Deferred Revenue, Refund Payments USD 14.13M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012382
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 8.13M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 28.98M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 188.27M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 28.90M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 932,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 84.92M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 25,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 24.43M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 9.08M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 2.63M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent USD 1.51M 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 187.34M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs USD 595,000 2016-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap DeferredTaxLiabilitiesGoodwillAndIntangibleAssets Deferred Tax Liabilities, Goodwill and Intangible Assets USD 108,000 2018-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 947,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxLiabilitiesNoncurrent Deferred Tax Liabilities, Net, Noncurrent USD 513,000 2016-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 15,000 2019-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap DeferredTaxLiabilitiesPrepaidExpenses Deferred Tax Liabilities, Prepaid Expenses USD 164,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD -179,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap Depreciation Depreciation USD 1.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 1.25M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-07 0001564590-19-030054
us-gaap DividendsCommonStock Dividends, Common Stock USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -1.16 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.014 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.101 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.003 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.008 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount USD 1.86M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.108 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.014 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure -0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure 0.027 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.021 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 7.20M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 7.30M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap FurnitureAndFixturesGross Furniture and Fixtures, Gross USD 1.05M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap GainLossOnDispositionOfAssets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property USD 293,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD -17,000 2017-01-01 2017-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap GainLossOnSalesOfAssetsAndAssetImpairmentCharges Gain (Loss) on Sale of Assets and Asset Impairment Charges USD -402,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 27.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap Goodwill Goodwill USD 949,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap GoodwillImpairmentLoss Goodwill, Impairment Loss USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 400,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -58.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IncomeLossFromContinuingOperationsPerBasicAndDilutedShare Income (Loss) from Continuing Operations, Per Basic and Diluted Share USD/shares -0.37 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007806
us-gaap IncomeLossFromContinuingOperationsPerBasicShare Income (Loss) from Continuing Operations, Per Basic Share USD/shares -0.29 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IncomeLossFromContinuingOperationsPerDilutedShare Income (Loss) from Continuing Operations, Per Diluted Share USD/shares -0.29 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IncomeTaxCreditsAndAdjustments Income Tax Credits and Adjustments USD 2.80M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-07 0000950170-23-060201
us-gaap IncomeTaxesPaid Income Taxes Paid USD 13.06M 2019-01-01 2019-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 0 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-03-27 0000950170-23-009984
us-gaap IncomeTaxesReceivable Income Taxes Receivable, Current USD 13.06M 2020-09-30 2020 Q3 10-Q 2020-11-05 0001564590-20-051302
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 180,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 1.72M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -3.60M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 49,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 142,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 11,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 238,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD 39,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD -355,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -294,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -1.51M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IncreaseDecreaseInAccountsReceivableRelatedParties Increase (Decrease) in Accounts Receivable, Related Parties USD -154,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -371,000 2016-01-01 2016-03-31 2016 Q1 10-Q 2016-05-06 0001564590-16-018134
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD 24.81M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -26.81M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-06 0001564590-18-027387
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD 56,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-11 0000950170-24-029191
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 6.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IncreaseInRestrictedCash Increase in Restricted Cash USD 817,000 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IndefiniteLivedIntangibleAssetsExcludingGoodwill Indefinite-lived Intangible Assets (Excluding Goodwill) USD 328,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IntangibleAssetsNetExcludingGoodwill Intangible Assets, Net (Excluding Goodwill) USD 1.75M 2016-03-31 2016 Q1 10-Q 2016-05-06 0001564590-16-018134
us-gaap InterestExpense Interest Expense USD 1.73M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 1.40M 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001564590-17-022252
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 220,000 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-03 0001564590-16-027405
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 2.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 7.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap IssuanceOfStockAndWarrantsForServicesOrClaims Issuance of Stock and Warrants for Services or Claims USD 0 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-03-27 0000950170-23-009984
us-gaap LeaseholdImprovementsGross Leasehold Improvements, Gross USD 1.60M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 10.12M 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034575
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 5.73M 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034575
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 4.39M 2022-12-31 2022 FY 10-K 2023-03-27 0000950170-23-009991
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 4.39M 2023-12-31 2023 FY 10-K 2024-03-11 0000950170-24-029191
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 4.39M 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034575
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 1.31M 2021-09-30 2021 Q3 10-Q 2021-11-04 0000950170-21-003053
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 731,000 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034575
us-gaap Liabilities Liabilities USD 79.79M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 364.68M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap LiabilitiesAssumed1 Liabilities Assumed USD 1.86M 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-03 0001564590-16-027405
us-gaap LiabilitiesCurrent Liabilities, Current USD 45.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap LicenseAndServicesRevenue License and Services Revenue (Deprecated 2018-01-31) USD 14.18M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012382
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 1.42M 2014-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 1.57M 2014-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap LongTermInvestments Long-term Investments USD 99.97M 2021-09-30 2021 Q3 10-Q 2021-11-04 0000950170-21-003053
us-gaap MachineryAndEquipmentGross Machinery and Equipment, Gross USD 14.00M 2022-12-31 2022 FY 10-K 2023-03-27 0000950170-23-009991
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 235.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 2.60M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012382
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -186.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -23.38M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012382
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -26.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -14.61M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012382
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -58.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -58.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OperatingExpenses Operating Expenses USD 80.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -66.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OperatingLeaseCost Operating Lease, Cost USD 5.07M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 5.10M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034575
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 9.38M 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034575
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 526,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 3.86M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OperatingLeasePayments Operating Lease, Payments USD 5.57M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034575
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 3.67M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 41.35M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 4.85M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 34.14M 2016-03-31 2016 Q1 10-Q 2016-05-06 0001564590-16-018134
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 5.27M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 5.13M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 4.99M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 21.11M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 1.17M 2017-09-30 2017 Q3 10-Q 2017-11-07 0001564590-17-022252
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 4.20M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.083 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034575
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.56M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 551,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -426,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD 1,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -8,000 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-23 0001564590-15-010977
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 4.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 305,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap PaymentOfFinancingAndStockIssuanceCosts Payment of Financing and Stock Issuance Costs USD 12,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap PaymentsForRestructuring Payments for Restructuring USD 2.69M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 15.00M 2026-03-19 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap PaymentsToAcquireAvailableForSaleSecurities Payments to Acquire Available-for-sale Securities USD 161.74M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-06 0001564590-18-027387
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 99.90M 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-03-27 0000950170-23-009984
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 99.90M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-04 0000950170-21-003053
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 589,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap PaymentsToAcquireShortTermInvestments Payments to Acquire Short-term Investments USD 376.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap PreferredStockDividendsAndOtherAdjustments Preferred Stock Dividends and Other Adjustments USD 6.71M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2015-10-14 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2015-10-14 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2017-09-30 2017 Q3 10-Q 2017-11-07 0001564590-17-022252
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2017-09-30 2017 Q3 10-Q 2017-11-07 0001564590-17-022252
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 6.65M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 81.78M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 228.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 74.43M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised USD 930,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-02 0001564590-17-003229
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 830,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 5.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ProceedsFromNotesPayable Proceeds from Notes Payable USD 3.36M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap ProceedsFromRepaymentsOfNotesPayable Proceeds from (Repayments of) Notes Payable USD -3.07M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 154.50M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-06 0001564590-18-027387
us-gaap ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments Proceeds from Sale, Maturity and Collection of Short-term Investments USD 190.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 100.00M 2023-01-01 2023-06-30 2023 Q2 10-Q 2023-08-08 0000950170-23-039761
us-gaap ProceedsFromSaleOfProductiveAssets Proceeds from Sale of Productive Assets USD 52,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 300,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 0 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-09 0000950170-23-019654
us-gaap ProductLiabilityContingencyAccrualDiscountRate Product Liability Contingency, Accrual, Discount Rate pure 0.09 2017-09-29 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -58.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 18.22M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 2.52M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap RepaymentsOfNotesPayable Repayments of Notes Payable USD 3.03M 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-03 0001564590-16-027405
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 53.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 10.70M 2017-01-01 2017-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 100,000 2014-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 917,000 2017-03-31 2017 Q1 10-Q 2017-05-05 0001564590-17-008943
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 917,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 610,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap RestructuringAndRelatedCostExpectedCost1 Restructuring and Related Cost, Expected Cost USD 2.94M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.4 2025-01-06 2026 Q1 10-Q 2026-05-07 0001193125-26-211868
us-gaap RestructuringCharges Restructuring Charges USD 7.15M 2022-07-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0000950170-22-023190
us-gaap RestructuringCosts Restructuring Costs USD 25,000 2025-04-01 2025-06-30 2025 Q3 10-Q 2025-11-06 0001193125-25-269477
us-gaap RestructuringReserve Restructuring Reserve USD 24,000 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap RestructuringReserveTranslationAndOtherAdjustment Restructuring Reserve, Translation and Other Adjustment USD -77,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -770.86M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 13.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap RevenueFromRelatedParties Revenue from Related Parties USD 2.20M 2016-01-01 2016-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap Revenues Revenues USD 13.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-03-27 0000950170-23-009984
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 5.3 2026-03-19 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 10.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage pure 0.021 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.689 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.629 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.019 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.014 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant shares 2.90M 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 12.00M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 11.35M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 6.63 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 470,100 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 3,811 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 779,898 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001564590-17-022252
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 9.028 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001564590-17-022252
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 425,574 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 4.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 1.41 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 24.59M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 20.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 5.04 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 6.84M 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 10.93M 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 10.77 2020-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008081
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 2.80M 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Payment Arrangement, Plan Modification, Incremental Cost USD 2.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 1.68 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 1.071 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 11.38 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 5.07 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price USD/shares 7.853 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable shares 4.52M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding shares 7.80M 2018-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap ShortTermInvestments Short-term Investments USD 77.50M 2015-09-30 2015 Q3 10-Q 2015-11-23 0001564590-15-010977
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 284.89M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.016 2015-10-01 2015-10-02 2016 FY 10-K 2017-03-02 0001564590-17-003229
us-gaap StockholdersEquityNoteSubscriptionsReceivable Stockholders' Equity Note, Subscriptions Receivable USD 78,000 2015-12-31 2016 FY 10-K 2017-03-02 0001564590-17-003229
us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Stock Issued During Period, Shares, Employee Stock Purchase Plans shares 383,346 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034575
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 346,998 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 246,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 159,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-02-27 0001564590-19-004890
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 228.35M 2026-01-01 2026-03-31 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 94,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap SubleaseIncome Sublease Income USD 1.19M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect USD 0 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-03-27 0000950170-23-009984
us-gaap TaxesPayableCurrent Taxes Payable, Current USD 13.34M 2018-12-31 2019 FY 10-K 2020-02-27 0001564590-20-007395
us-gaap TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests USD 159.08M 2015-09-30 2015 Q3 10-Q 2015-11-23 0001564590-15-010977
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 22.00M 2014-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 18.70M 2014-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2017-12-31 2017 FY 10-K 2018-03-07 0001564590-18-004727
us-gaap TemporaryEquityValueExcludingAdditionalPaidInCapital Temporary Equity, Par Value USD 76.71M 2014-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 20.21M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 400,000 2023-09-30 2023 Q3 10-Q 2023-11-07 0000950170-23-060201
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 4.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense Unrecognized Tax Benefits, Income Tax Penalties Expense USD 1.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 213,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD -41,000 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-07 0001564590-16-014091
us-gaap UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense Unrecognized Tax Benefits, Interest on Income Taxes Expense USD 1.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 2.30M 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 5.00M 2023-09-01 2023-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap VariableLeaseCost Variable Lease, Cost USD 2.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-16 0001193125-26-107146
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 205.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 65.39M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007806
us-gaap WeightedAverageNumberOfSharesContingentlyIssuable Weighted Average Number of Shares, Contingently Issuable shares 846,637 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap WeightedAverageNumberOfSharesIssuedBasic Weighted Average Number of Shares Issued, Basic shares 204.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 205.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449739

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →